D
Dominique Stoppa-Lyonnet
Researcher at Curie Institute
Publications - 444
Citations - 32995
Dominique Stoppa-Lyonnet is an academic researcher from Curie Institute. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 80, co-authored 420 publications receiving 29316 citations. Previous affiliations of Dominique Stoppa-Lyonnet include PSL Research University & Bosch.
Papers
More filters
Journal ArticleDOI
Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel
Yael Laitman,Roni Tsipora Borsthein,Dominique Stoppa-Lyonnet,Dominique Stoppa-Lyonnet,Dominique Stoppa-Lyonnet,Efrat Dagan,Laurent Castera,Maud Goislard,Ruth Gershoni-Baruch,Hadassah Goldberg,Bella Kaufman,Bella Kaufman,Noa Ben-Baruch,Jamal Zidan,Taiseer Maray,Lior Soussan-Gutman,Eitan Friedman,Eitan Friedman +17 more
TL;DR: There are no predominant recurring germline mutations in BRCA1 or BRCa2 genes among ethnically diverse Jewish and non Jewish high risk families in Israel.
Journal ArticleDOI
Current Policies for Surveillance and Management in Women at Risk for Breast and Ovarian Cancer: A Survey among 16 European Family Cancer Clinics
Hans F. A. Vasen,Neva E. Haites,D G R Evans,C. M. Steel,Pål Møller,Shirley Hodgson,D. Eccles,Patrick J. Morrison,Dominique Stoppa-Lyonnet,Jenny Chang-Claude,Ma Caligo +10 more
TL;DR: Evaluated the management and screening protocols implemented in high risk families at various family cancer clinics in Europe for the identification of carriers within affected families with a 50– 85% risk of developing breast or ovarian cancer.
Journal ArticleDOI
External quality assessment for mutation detection in the BRCA1 and BRCA2 genes: EMQN's experience of 3 years
TL;DR: From the reported data it is clear that external quality control should become an integral part of quality assessment in the laboratory, thus contributing to maintaining confidence in the reliability of genetic testing among patients and health professionals.
Journal ArticleDOI
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA).
Ana Osorio,Roger L. Milne,Guillermo Pita,Paolo Peterlongo,Tuomas Heikkinen,Jacques Simard,Georgia Chenevix-Trench,Amanda B. Spurdle,Jonathan Beesley,Xiaoqing Chen,Sue Healey,Susan L. Neuhausen,Yuan Chun Ding,Fergus J. Couch,Xianshu Wang,Noralane M. Lindor,Siranoush Manoukian,M. Barile,Alessandra Viel,Laura Tizzoni,Csilla Szabo,Lenka Foretová,Michal Zikan,Kathleen Claes,Mark H. Greene,Phuong L. Mai,Gad Rennert,Flavio Lejbkowicz,Ofra Barnett-Griness,Irene L. Andrulis,Irene L. Andrulis,Hilmi Ozcelik,Nayana Weerasooriya,Anne-Marie Gerdes,Mads Thomassen,Dorthe G. Crüger,Maria A. Caligo,Eitan Friedman,Eitan Friedman,Bella Kaufman,Bella Kaufman,Yael Laitman,Scott A. Cohen,T. Kontorovich,Ruth Gershoni-Baruch,Efrat Dagan,Helena Jernström,Marie Stenmark Askmalm,Brita Arver,Beatrice Malmer,Susan M. Domchek,Katherine L. Nathanson,Joan Brunet,T. Ramón y Cajal,Drakoulis Yannoukakos,Ute Hamann,Frans B. L. Hogervorst,Senno Verhoef,E. B Gómez Garcíla,Juul T. Wijnen,A. M. W. Van Den Ouweland,Douglas F. Easton,Susan Peock,M. Cook,Clare Oliver,Debra Frost,Craig Luccarini,D G R Evans,Fiona Lalloo,Rosalind A. Eeles,Gabriella Pichert,J. Cook,Shirley Hodgson,Patrick J. Morrison,Fiona Douglas,A. K. Godwin,Olga M. Sinilnikova,Laure Barjhoux,Dominique Stoppa-Lyonnet,V. Moncoutier,S. Giraud,C. Cassini,L. Olivier-Faivre,Françoise Révillion,Jean-Philippe Peyrat,Danièle Muller,Jean-Pierre Fricker,Henry T. Lynch,Esther M. John,Saundra S. Buys,M. Daly,John L. Hopper,M. B. Terry,A. Miron,Yosuf Yassin,David E. Goldgar,Christian F. Singer,Daphne Gschwantler-Kaulich,Georg Pfeiler,A. C. Spiess,Thomas v O Hansen,Oskar T. Johannsson,Tomas Kirchhoff,Kenneth Offit,Kristi Kosarin,Marion Piedmonte,Gustavo C. Rodriguez,Katie Wakeley,John F. Boggess,Jack Basil,Peter E. Schwartz,Stephanie V. Blank,Amanda E. Toland,M. Montagna,Cinzia Casella,Evgeny N. Imyanitov,Anna Allavena,Rita K. Schmutzler,B. Versmold,C. Engel,Alfons Meindl,N. Ditsch,Norbert Arnold,Dieter Niederacher,H. Deiler,Britta Fiebig,Raymonda Varon-Mateeva,Dieter Schaefer,Ursula G. Froster,T. Caldes,M. De La Hoya,Lesley McGuffog,Antonis C. Antoniou,Heli Nevanlinna,Paolo Radice,Javier Benitez +135 more
TL;DR: The role of a SNP in intron 1 of the ERCC4 gene (rs744154), previously reported to be associated with a reduced risk of breast cancer in the general population, as a breast cancer risk modifier in BRCA1 and BRCa2 mutation carriers is evaluated.
Journal ArticleDOI
Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers
Ana-Teresa Maia,Antonis C. Antoniou,Martin O'Reilly,Shamith A. Samarajiwa,Mark J Dunning,Christiana Kartsonaki,Suet-Feung Chin,Christina Curtis,Lesley McGuffog,Susan M. Domchek,Douglas F. Easton,Susan Peock,Debra Frost,D G R Evans,Ros Eeles,Louise Izatt,Julian Adlard,Diana Eccles,Olga M. Sinilnikova,Sylvie Mazoyer,Dominique Stoppa-Lyonnet,Marion Gauthier-Villars,Laurence Faivre,Laurence Venat-Bouvet,Capucine Delnatte,Heli Nevanlinna,Fergus J. Couch,Andrew K. Godwin,Maria A. Caligo,Rosa B. Barkardottir,Xiaoqing Chen,Jonathan Beesley,Sue Healey,Carlos Caldas,Georgia Chenevix-Trench,Bruce A.J. Ponder +35 more
TL;DR: This work identified small-effect genetic variants associated with allelic expression differences in BRCA2 which could possibly affect the risk in mutation carriers through altering expression levels of the wild-type allele.